Our diagnosis and treatment methods for a case of brain tumors in Kansai Medical University Hirakata Hospital

Abstract

　Department of Neurosurgery of Kansai Medical Unicversity was found in 1966 by Professor Naoki Kageyama. Since then, our department has been playing an important role in the field of neuro-oncology. Recently, several evidence-based therapeutic tools have come up to the field of glioblastoma treatment. Above all, bevacizumab has drastic effects prolonging the PFS in the first line treatment and the OS in the second line one against recurrence. In our department, patients have rights to choose whether to use bevacizumab in the first line or the second except patients with poor ADL. Patients with poor ADL are recommended to have bevacizumab from the first line treatment expecting super-steroid effect.